http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
주인명,김수자,이강우,이명희,박금민,오현애,윤대두,김선자 대한산부인과학회 1994 Obstetrics & Gynecology Science Vol.37 No.4
저자들은 1990년 10월 28일 17세 초산부로부터 임신 44^+1주에 제왕절개술로 분만된 신생아에서 부검상 전신부종과 흉강, 심낭 및 복강내 삼출액 축적을 보였던 비면역성 태아수종 1에를 경험하였기에 문헌고찰과 함께 보고하는 바이다. Nonimmune hydrops fetalis is defined as a pathologic and generalized abnormal accumulation of serous fluid in the entire body tissue and cavities unassociated with erythroblastosis. With the widespread introduction of immunoprophylaxis, there is a decline in rhesus isoimmunization and nonimmune hydrops fetalis (NIHF) becomes increasingly important. NIHF now accounts for 80% of all hydropic fetuses and its contribution to the perinatal mortality increased up to 3%. Now we report a case of NIFH with generalized edema, pericardial and pleural fluid accumulation and ascites found at autopsy. No other deformity was found.
Yoon,SK,Lee,CD,Chung,KW,Park,YM,Choi,SW,Bae,SH,Choi,JY,Cho,SH,Byun,BH,Yang,JM,Park,DH,Kim,BS,Sun,HS 가톨릭중앙의료원 가톨릭암센터 1998 암심포지움 Vol.- No.2
여러 가지 치료법이 적용되고 있음에도 불고하고 TNM Ⅲ기 이상의 진행성 간암(Hepatocellular carcinoma)에 대해서는 치료성적이 매우 불량하다. 최근 소개된 ECF(Epirubicin, Cisplatin, 5-FU) 전신화학요법은 췌.담도계 악성종양에 대한 치료반응율이 40% 정도로서 비교적 양호하다고 보고되었다. 본 연구자들은 진행성 간암의 치료효율을 향상시키기 위한 다각적 치료법(multimodality therapy)으로서 ECF화학요법을 근간으로 하는 새로운 병합치료방법(Alternative tratment of systemic ECFand transcather arterial EC-chemoembolization)을 시도하였으며, 그 치료결과를 보고한다.
( Ki Tae Yoon ),( Youn Jae Lee ),( Seung Ha Park ),( Young Seok Kim ),( Jeong Won Jang ),( Jun Yong Park ),( June Sung Lee ),( Jeong Heo ),( Mong Cho ),( Sung Jae Park ),( Eun Uk Jung ),( Jung Hyun Kw 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background: Standard treatment in patients with hepatitis C virus (HCV) genotype 2 is the combination of peginterferon (pegIFN) α and ribavirin (RBV) for 24 weeks. There were several studies to investigate whether a shorter course treatment is as effective as a standard 24-week treatment. In spite of the short duration, some studies have shown the sufficient efficacy, especially in patients who had a rapid virologic response (RVR) at 4 weeks. But some other studies have reported conflicting results. We investigate the 16 weeks of treatment with pegIFN and weight-based RBV is as effective as 24 weeks in patients who achieve RVR with genotype 2 chronic hepatitis C (CHC). Methods: This is a prospective, randomized, controlled study. Patients with genotype 2 CHC were treated with pegIFN α-2a (180 μg/week) and weight-based RBV 800-1200 mg/day. The only patients who achieve RVR at week 4 were randomized in a 1:1 ratio to 16 or 24 weeks. We are conducting the study and will enroll a total of 164 patients. Now, 84 patients who have completed the study are included in this interim analysis. The primary end point was sustained virologic response (SVR) which was defined as not detectable HCV RNA at 24 weeks after the completion of treatment. Results: There was no statistically difference in SVR (90.7% in 16 weeks vs. 92.7% in 24 weeks, p=0.999). End of treatment virologic reponse was 100% in the 16 weeks group and 97.6% in the 24 weeks group (p=0.488). Relapse rate was 9.3% in the 16 weeks group and 4.9% in the 24 weeks group (p=0.676). Conclusions: A shorter course of therapy for 16 weeks with pegIFN α-2a and weigh-based RBV is as effective as a 24 weeks treatment in patients who achieve RVR with genotype 2 CHC.
( Ki Tae Yoon ),( Youn Jae Lee ),( Seung Ha Park ),( Young Seok Kim ),( Jeong Won Jang ),( Jun Yong Park ),( June Sung Lee ),( Jeong Heo ),( Mong Cho ),( Sung Jae Park ),( Eun Uk Jung ),( Jung Hyun Kw 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: Standard treatment in patients with hepatitis C virus (HCV) genotype 2 is the combination of peginterferon (pegIFN) α and ribavirin (RBV) for 24 weeks. There were several studies to investigate whether a shorter course treatment is as effective as a standard 24-week treatment. In spite of the short duration, some studies have shown the sufficient efficacy, especially in patients who had a rapid virologic response (RVR) at 4 weeks. But some other studies have reported conflicting results. We investigate the 16 weeks of treatment with pegIFN and weight-based RBV is as effective as 24 weeks in patients who achieve RVR with genotype 2 chronic hepatitis C (CHC). Methods: This is a prospective, randomized, controlled study. Patients with genotype 2 CHC were treated with pegIFN α-2a (180 μg/week) and weight-based RBV 800-1200 mg/day. The only patients who achieve RVR at week 4 were randomized in a 1:1 ratio to 16 or 24 weeks. We are conducting the study and will enroll a total of 164 patients. Now, 84 patients who have completed the study are included in this interim analysis. The primary end point was sustained virologic response (SVR) which was defined as not detectable HCV RNA at 24 weeks after the completion of treatment. Results: There was no statistically difference in SVR (90.7% in 16 weeks vs. 92.7% in 24 weeks, p=0.999). End of treatment virologic reponse was 100% in the 16 weeks group and 97.6% in the 24 weeks group (p=0.488). Relapse rate was 9.3% in the 16 weeks group and 4.9% in the 24 weeks group (p=0.676). Conclusions: A shorter course of therapy for 16 weeks with pegIFN α-2a and weigh-based RBV is as effective as a 24 weeks treatment in patients who achieve RVR with genotype 2 CHC.
사염화탄소로 인한 간 독성에 미치는 진달래(Rhododendron mucronulatum)화분의 영향
윤수홍(Soo-Hong Yoon),강정혜(Jeong-Hae Kang),권정숙(Chŏng-Suk Kwŏn) 한국식품영양과학회 1989 한국식품영양과학회지 Vol.18 No.4
Nutritional value of azalea pollen and its effect on the carbontetrachloride induced liver damage were investigated in this experiment. Azalea pollen was primary composed of 58.96% of carbohydrate, 21.86% crude protein. 2.26% fat, and 2.89% ash. 17 amino acids and 22 fatty acids were quantitatively analyzed, and the major component of them was lysine, and linolenic acid, respectively. After administration of pollen and carbontetrachloride concomitantly, serum ALT, AST, LDH activites and tissue lipid peroxidation decreased significantly, but serum total lipid and cholesterol levels did not changed.
Novel combination markers for predicting progression of nonmuscle invasive bladder cancer
Ha, Yun‐,Sok,Kim, Ji Sang,Yoon, Hyung‐,Yoon,Jeong, Pildu,Kim, Tae‐,Hwan,Yun, Seok‐,Joong,Lee, Sang‐,Cheol,Kim, Gi‐,Young,Choi, Yung‐,Hyun,Moon, Sung‐,Kw Wiley Subscription Services, Inc., A Wiley Company 2012 International journal of cancer: Journal internati Vol.131 No.4
<P><B>Abstract</B></P><P>To identify prognostic markers in nonmuscle invasive bladder cancer (NMIBC), the combined effect of <I>RUNX3</I> and <I>MGC17624</I> for predicting NMIBC progression was assessed. <I>RUNX3</I> promoter methylation was examined using methylation specific‐polymerase chain reaction (MS‐PCR). <I>MGC17624</I> mRNA expression was evaluated by real‐time PCR. Patients were divided into three groups according to the status of the two genes and the prognostic effects of these markers were evaluated. The median follow‐up period was 57.8 months (range, 9.1–189.7). The mRNA expression level of <I>MGC17624</I> was significantly lower in patients with positive <I>RUNX3</I> methylation than in those with negative methylation (<I>p</I> = 0.047). Kaplan–Meier estimates showed significant differences in time‐to‐progression between the genetic combination predictors (log‐rank test; <I>p</I> < 0.001). Patients with a poor predictive combination were at a significantly higher risk for progression [Hazard ratio (HR), 22.579] than patients with a good predictive combination in multivariate Cox regression analysis. In the subgroup analysis, a poor predictive combination accurately estimated progression in patients with intravesical therapy (HR, 20.081) and in those who experienced recurrence (HR, 54.233). Assessment of the status of <I>RUNX3</I> and <I>MGC17624</I> in combination was identified as a reliable method for predicting NMIBC progression.</P>
주인명,김수자,이강우,이명희,김지수,윤재영,오현애 대한산부인과학회 1992 Obstetrics & Gynecology Science Vol.35 No.10
본 증례의 원인적 요소로서는 다발성 난소낭종과 그리고 임신으로 인한 골반울혈, 자궁비대 및 급격한 체위변동으로 인하여 발생되었다고 생각되며 문헌적 고찰과 함께 보고하는 바이다. Acute pelvic pain is a common symptom encountered by the gynecologist. Torsion of the tube should always be considered in acute abdominal pain. Acute diagnosis and prompt treatment can prevent of complications, such as necrosis of the ovary and tube, peritonitis, shock, and rarely death. Torsion of the fallopian tube have been repotered not infrequently, this complication in pregnancy seems to be relatively rare. We experienced a case of torsion of the fallopian tube in pregnancy and report it with brief review of the literature.